Apr 16, 2021
Facing a sudden surge in COVID-19 infections, India is once again home to the world’s second-largest outbreak overtaking Brazil after the latter moved ahead in March. But behind the bleak statistical jockeying is an epidemiological enigma over why the Latin American country has been far more devastated by the pathogen.
When it comes to the scale of infections, the two nations are similarly matched, with cases hovering around 14 million and hospitals from Mumbai to Sao Paulo under increasing pressure as admissions continue to rise.
But it’s the divergence in fatalities that has scientists puzzled. Brazil, home to almost 214 million, has seen more than 365,000 people die from COVID-19. That’s more than double the number of deaths in India, which has a far greater population of 1.4 billion.
830 Hyderabad-based Bharat Biotech and the Indian Council for Medical Research have developed Covaxin, one of the two vaccines being used in the ongoing nationwide COVID-19 vaccination drive. PTI file
New Delhi, April 16
The production of indigenously developed COVID-19 vaccine Covaxin will be ramped up significantly and increased to 10 crore doses per month by September, the Department of Biotechnology said on Friday.
Covaxin’s production will be doubled by May-June and the department has roped in three public sector companies to increase the capacity of vaccine production, it said.
Few weeks ago, inter-ministerial teams had visited the sites of two main vaccine manufacturers in India to get their inputs on how production can be ramped up.
India has over 16 lakh active COVID-19 cases - the highest since the pandemic began (File)
New Delhi:
As India battles a second, and even bigger, wave of coronavirus cases - this morning over 2.17 lakh new cases were reported in the past 24 hours - and the government s handling of the pandemic and vaccination drive come under scrutiny, an NDTV analysis suggests a flip-flop on key policies and decisions may have led to a delay in taking and implementing crucial measures.
Vaccine Diplomacy: The export of millions of doses of vaccines was praised by the global community, with the World Health Organisation hailing the promotion of vaccine equity. However, as states ran out of doses the question arose - did the government miscalculate requirements?
Covid-19: Centre ropes in PSUs to ramp up vaccine production
Top Searches
Covid-19: Centre ropes in PSUs to ramp up vaccine production
PTI / Apr 16, 2021, 18:24 IST
FacebookTwitterLinkedinEMail
NEW DELHI: The production of indigenously developed Covid-19 vaccine Covaxin will be ramped up significantly and increased to 10 crore doses per month by September, the Department of Biotechnology said on Friday.
Covaxin s production will be doubled by May-June and the department has roped in three public sector companies to increase the capacity of vaccine production, it said.
Few weeks ago, inter-ministerial teams had visited the sites of two main vaccine manufacturers in India to get their inputs on how production can be ramped up.
Congress leader Rahul Gandhi. File
| Photo Credit:
PTI
After imposing a ‘Tughlaqi lockdown,’ Centre is now banking on divine intervention to fight the virus, he says
Former Congress chief Rahul Gandhi, in a tweet, on Friday slammed the Narendra Modi government’s strategy and claimed that after imposing a “Tughlaqi lockdown,” it is now banking on divine intervention to fight COVID-19.
Mr. Gandhi, who was scheduled to address a press conference on the second wave, however, cancelled it.
Party insiders say he along with other senior leaders may do so after a virtual meeting of the Congress Working Committee (CWC) on Saturday.